Nuveen
ADMA icon

Nuveen’s ADMA Biologics ADMA Stock Holding History

Nuveen’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Sell
3,260,349
-2,837,876
-47% -$25.9M 0.01% 1073
2026
Q1 		$54.9M Buy
6,098,225
+171,835
+3% +$2.71M 0.01% 601
2025
Q4 		$108M Buy
5,926,390
+202,245
+4% +$3.41M 0.03% 382
2025
Q3 		$83.9M Buy
5,724,145
+161,241
+3% +$2.76M 0.02% 452
2025
Q2 		$101M Buy
5,562,904
+848,043
+18% +$17.3M 0.03% 388
2025
Q1 		$93.5M Buy
4,714,861
+162,544
+4% +$2.81M 0.03% 411
2024
Q4 		$78.1M Sell
4,552,317
-2,025,560
-31% -$38.1M 0.02% 466
2024
Q3 		$131M Sell
6,577,877
-2,347,261
-26% -$36.5M 0.04% 355
2024
Q2 		$99.8M Sell
8,925,138
-1,536,238
-15% -$12.9M 0.03% 407
2024
Q1 		$69.1M Sell
10,461,376
-894,101
-8% -$4.89M 0.02% 531
2023
Q4 		$51.3M Buy
11,355,477
+669,543
+6% +$2.48M 0.02% 594
2023
Q3 		$38.3M Buy
10,685,934
+2,126,797
+25% +$8.19M 0.01% 680
2023
Q2 		$31.6M Sell
8,559,137
-473,176
-5% -$1.75M 0.01% 793
2023
Q1 		$29.9M Buy
9,032,313
+1,479,806
+20% +$5.12M 0.01% 792
2022
Q4 		$29.3M Sell
7,552,507
-1,151,226
-13% -$3.55M 0.01% 810
2022
Q3 		$21.1M Buy
8,703,733
+1,541,544
+22% +$3.7M 0.01% 972
2022
Q2 		$14.2M Sell
7,162,189
-432,751
-6% -$851K 0.01% 1284
2022
Q1 		$11.8M Sell
7,594,940
-3,017,660
-28% -$4.71M ﹤0.01% 1544
2021
Q4 		$15M Buy
10,612,600
+3,727,960
+54% +$4.9M ﹤0.01% 1426
2021
Q3 		$7.78M Buy
6,884,640
+980,981
+17% +$1.37M ﹤0.01% 1961
2021
Q2 		$9.45M Sell
5,903,659
-855,303
-13% -$1.5M ﹤0.01% 1905
2021
Q1 		$11.9M Buy
6,758,962
+6,502,025
+2,531% +$14.9M ﹤0.01% 1688
2020
Q4 		$501K Buy
256,937
+1,407
+0.6% +$2.96K ﹤0.01% 3043
2020
Q3 		$611K Sell
255,530
-119,214
-32% -$327K ﹤0.01% 2881
2020
Q2 		$1.1M Sell
374,744
-385,832
-51% -$1.11M ﹤0.01% 2587
2020
Q1 		$2.19M Buy
760,576
+481,876
+173% +$1.67M ﹤0.01% 2145
2019
Q4 		$1.11M Buy
278,700
+144,913
+108% +$632K ﹤0.01% 2647
2019
Q3 		$595K Buy
133,787
+64,693
+94% +$270K ﹤0.01% 2887
2019
Q2 		$268K Buy
+69,094
New +$305K ﹤0.01% 3130

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen's ADMA Position: Q2 2026 in Review

Nuveen reduced its ADMA Biologics (ADMA) stake by 47% in Q2 2026, selling an estimated $25.9M and leaving 3,260,349 shares worth $27.3M. The position accounts for 0.01% of the portfolio, ranked #1073.

Nuveen first reported a position in ADMA in Q2 2019 and has held it in 29 quarters since. The position peaked at $131M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Nuveen held 3,260,349 shares of ADMA Biologics worth $27.3M as of Q2 2026.
  • Nuveen sold 2,837,876 ADMA Biologics shares in Q2 2026, an estimated $25.9M.
  • ADMA Biologics made up 0.01% of Nuveen's portfolio in Q2 2026, its #1073 holding.
  • Nuveen first reported a position in ADMA Biologics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's ADMA Biologics position peaked at $131M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.